Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes
← catalyst calendarNCT07392125 · readout in 88 d
Sponsored by Achieve Life Sciences (industry) · ACHV — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
800estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-15 | estimated | When the study began enrolling |
| Primary completion | 2026-11-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Vaping Cessation
Interventions
- Drug: Cytisinicline — also filed as cytisine
- Drug: Placebo
- Behavioral: Behavioral Support
Primary outcome
what the primary-completion date above is the date OFPrimary Efficacy Objective
measured Randomization to Week 24 follow-up visit
Permalink · ACHV's whole pipeline · Catalyst calendar · Every registered study · What changed